← Back to Screener
Anbio Biotechnology Class A Ordinary Shares (NNNN)
Price$22.99
Value ScoreF
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-9.80%
Price vs S&P 500 (4W)-11.02%
VGM Score42.02
Market Capitalization$3.31B
P/E Ratio (Annual)516.60x
All Metrics
P/CF (Annual)1994.73x
Book Value / Share (Quarterly)$0.21
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-28.39%
Cash Flow / Share (Quarterly)$0.01
Price vs S&P 500 (YTD)-31.70%
Gross Margin (TTM)89.00%
Net Profit Margin (TTM)77.10%
EPS (TTM)$0.23
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$0.23
EPS (Annual)$0.15
ROI (Annual)21.24%
Gross Margin (Annual)87.24%
Net Profit Margin (5Y Avg)47.28%
Cash / Share (Quarterly)$0.08
P/E Basic Excl Extra (TTM)324.28x
Revenue Growth QoQ (YoY)5.64%
P/E Normalized (Annual)516.60x
ROA (Last FY)21.17%
Revenue Growth TTM (YoY)-5.72%
EBITD / Share (TTM)$0.13
ROE (5Y Avg)46.01%
Operating Margin (TTM)69.04%
Cash Flow / Share (Annual)$-0.05
P/B Ratio109.70x
P/B Ratio (Quarterly)143.49x
Net Income / Employee (Annual)$237,200
Net Interest Coverage (TTM)44.91x
ROA (TTM)35.22%
EPS Growth QoQ (YoY)161.32%
EPS Incl Extra (Annual)$0.15
Current Ratio (Annual)344.29x
Quick Ratio (Quarterly)177.11x
3-Month Avg Trading Volume0.04M
52-Week Price Return175.00%
EV / Free Cash Flow (Annual)1992.16x
P/E Incl Extra (TTM)324.28x
Revenue / Employee (TTM)$490,100
P/S Ratio (Annual)382.57x
Asset Turnover (Annual)0.29x
52-Week High$55.65
Operating Margin (5Y Avg)43.81%
EPS Excl Extra (Annual)$0.15
26-Week Price Return-1.88%
Quick Ratio (Annual)177.12x
13-Week Price Return5.46%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)344.29x
Enterprise Value$3.30B
Asset Turnover (TTM)0.46x
Revenue / Employee (Annual)$320,300
Pretax Margin (Annual)74.06%
Cash / Share (Annual)$0.08
3-Month Return Std Dev82.42%
Gross Margin (5Y Avg)63.99%
Net Income / Employee (TTM)$377,800
ROE (Last FY)21.24%
EPS Basic Excl Extra (Annual)$0.15
P/FCF (TTM)1590.11x
Receivables Turnover (TTM)5.61x
EV / Free Cash Flow (TTM)1586.38x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.23
Receivables Turnover (Annual)3.66x
ROI (TTM)35.36%
P/S Ratio (TTM)250.01x
Pretax Margin (5Y Avg)47.28%
Revenue / Share (Annual)$0.20
Price vs S&P 500 (52W)150.63%
P/E Ratio (TTM)324.28x
EPS Growth TTM (YoY)69.57%
Year-to-Date Return-23.55%
5-Day Price Return-23.80%
EPS Normalized (Annual)$0.15
ROA (5Y Avg)34.25%
Net Profit Margin (Annual)74.06%
Month-to-Date Return-33.19%
EBITD / Share (Annual)$0.13
EPS Growth (3Y)-13.70%
Operating Margin (Annual)66.70%
P/CF (TTM)1590.11x
ROI (5Y Avg)46.01%
P/E Excl Extra (TTM)324.28x
EPS Basic Excl Extra (TTM)$0.23
P/B Ratio (Annual)143.49x
Pretax Margin (TTM)77.10%
Book Value / Share (Annual)$0.21
Price vs S&P 500 (13W)-2.80%
Beta2.93x
P/FCF (Annual)1590.11x
Revenue / Share (TTM)$0.30
ROE (TTM)35.36%
52-Week Low$7.92
vGradeF
gGradeB
mGradeB
vgmGradeC
Show chart for
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | B | $22.99 |
| IDXXIdexx Laboratories Inc | D | B | C | $562.16 |
| LNTHLantheus Holdings, Inc | C | B | B | $100.98 |
| CLDXCelldex Therapeutics, Inc | F | F | C | $28.62 |
| NEOGNeogen Corp | C | C | B | $8.90 |
| NTLAIntellia Therapeutics, Inc | D | C | B | $13.54 |
| QDELQuidelOrtho Corporation Common Stock | C | C | D | $14.33 |
| ACHVAchieve Life Sciences, Inc. | F | F | B | $5.13 |
| MYGNMyriad Genetics Inc | C | C | C | $4.57 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $4.56 |
| IMDXInsight Molecular Diagnostics Inc. Common Stock | F | D | C | $5.24 |
About
Anbio Biotechnology is an in vitro diagnostics company offering laboratory, point-of-care, and at-home testing solutions across infectious diseases, oncology, cardiovascular health, and other clinical domains. Its product portfolio includes automated analyzers such as the AF-1200 fluorescence immunoassay and SHA-100 dry chemistry systems, along with rapid diagnostic kits for conditions including COVID-19, dengue, and hepatitis. The company generates revenue primarily from Europe, with significant presence in South America and Asia-Pacific.